Peptides · Peptide comparison
Crystagen vs Vilon
Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides
Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Immune Rejuvenation
Healthy Aging
Cancer Defense
Immune System Revival
Digestive Support
Technical data
Compound specifications
Crystagen
- Molecular formula
- C14H21N3O8
- Molecular weight
- 359.3 g/mol
- Half-life
- Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
- Bioavailability
- Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
- CAS number
- Not assigned (patented as immunogeroprotective peptide, US8057810B2)
Vilon
- Molecular formula
- C11H21N3O5
- Molecular weight
- 275.3 g/mol
- Half-life
- Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids
- Bioavailability
- Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure
- CAS number
- 45234-02-4
Protocols
Dosing compared
Crystagen
Subcutaneous
- 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]
Intramuscular
- 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsCan also be given as an intramuscular injection at a similar dose, used in research practice. [6]
Oral
- 1-2 capsules (10 mg each)1-2 times daily with meals · 10-30 day course, repeated every 4-6 monthsThe oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]
Vilon
Subcutaneous injection
- 200–500 mcgOnce daily · 5–10 day courseCommon Khavinson-style introductory protocol for the KE (Lys-Glu) immune bioregulator; courses repeated 2–3 times yearly [6]. Research use only — no approved product.
- 500 mcgOnce daily · 10–12 day courseTypical full-course practice dose; cycle repeated every 3–6 months [6].
Intramuscular injection
- 500 mcgOnce daily · 10–12 day courseIntramuscular delivery is also documented for the injectable KE bioregulator; same per-course dosing as subcutaneous [6].
Applications
Best suited for
Crystagen
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting immune function during and after illness recovery
- Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
- Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Vilon
- Immune system restoration in aging individuals with declining thymic function
- Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Adjunctive immunomodulatory support during cancer treatment protocols
- Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
- Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Comprehensive Khavinson bioregulator protocols for anti-aging and immune support
- Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Crystagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Minor digestive changes
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Vilon
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Digestive changes
Uncommon
- Flu-like symptoms
Serious
- No documented serious adverse effects
Research status
Safety & evidence
Crystagen
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active autoimmune disease in flare without physician supervision
- Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Vilon
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.
Contraindications
- Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Active autoimmune disease in flare without medical supervision
- Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens
Decision guide
Which is right for you?
Crystagen
Choose Crystagen if…
- Restoring thymic function and immune competence in aging individuals with immune senescence
- Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
- Supporting immune function during and after illness recovery
- Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Vilon
Choose Vilon if…
- Immune system restoration in aging individuals with declining thymic function
- Adjunctive immunomodulatory support during cancer treatment protocols
- Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
- Comprehensive Khavinson bioregulator protocols for anti-aging and immune support